Showing results (351-360 of 4,238) with videos related to
Sort By:
Pageof 424
Journal for Immunotherapy of Cancer|October 8, 2025
Fungal microbiota signatures anticipate neoadjuvant immunochemotherapy outcomes in esophageal cancerLiping Liang, Shijie Mai, Gautam Sethi, et al.Journal for Immunotherapy of Cancer|October 28, 2025
Targeting PD-L1-CMTM6 interactions in myeloid cells triggers PD-L1 degradation and enhances cytotoxic T-cell expansionMichelle A Hsu, Xin Liu, Whitney Barham, et al.Journal for Immunotherapy of Cancer|October 28, 2025
Combination of a novel TCR Vβ chain-directed selective T cell activator with standard of care therapy for head and neck cancer improves antitumor responses and promotes regression of checkpoint-refractory tumor modelsFrancesca Rosato, Ginette Santiago-Sanchez, Kellsye P Fabian, et al.Journal for Immunotherapy of Cancer|October 6, 2025
O-GlcNAc transferase promotes immune evasion and immunotherapy resistance in uterine corpus endometrial cancer by targeting the glucocorticoid receptorJingjing Wang, Yang Xie, Li Liu, et al.Journal for Immunotherapy of Cancer|September 29, 2025
Transformer-based AI approach to unravel long-term, time-dependent prognostic complexity in patients with advanced NSCLC and PD-L1 ≥50%: insights from the pembrolizumab 5-year global registryAlessio Cortellini, Valentina Santo, Leonardo Brunetti, et al.Journal for Immunotherapy of Cancer|September 25, 2025
Novel oncolytic adenovirus-based PEPvIII vaccine displays a super antitumor effect in glioma modelsYuankun Chen, Lingyue Ren, Xia Li, et al.Journal for Immunotherapy of Cancer|July 11, 2025
Commentary on differential impact of TIM-3 ligands on NK cell functionRieneke van de VenJournal for Immunotherapy of Cancer|July 10, 2025
Enhancing outcomes in medically inoperable early-stage NSCLC with gut-targeted antibiotics and stereotactic body radiotherapy: results from a randomized pilot studySteven Joel Feigenberg, Francesca Costabile, Ceylan Tanes, et al.Journal for Immunotherapy of Cancer|July 15, 2025
Engineered IL-18 variants with half-life extension and improved stability for cancer immunotherapyTravis W Bainbridge, Lifen Wang, Marina Moskalenko, et al.Journal for Immunotherapy of Cancer|July 18, 2025
Therapeutic potential of T-cell receptor targeting the HLA-A*11:01-restricted KRASG12V neoantigen without cross-recognition of the self-antigen RAB7B in solid tumorsMeiying Shen, Yanan Hao, Xiaxia Han, et al.Pageof 424